Currently out of the existing stock ratings of Jonathan Aschoff, 80 are a BUY (86.02%), 10 are a HOLD (10.75%), 3 are a SELL (3.23%).

Jonathan Aschoff

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Aschoff works with a stock forecast success ratio of 32.93% fulfilled within 208.92 days on average.

Jonathan Aschoff’s has documented 158 price targets and ratings displayed on 27 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on MBRX, Moleculin Biotech at 12-Apr-2024.

Wall Street Analyst Jonathan Aschoff

Analyst best performing recommendations are on PBLA (PANBELA THERAPEUTICS).
The best stock recommendation documented was for PBLA (PANBELA THERAPEUTICS) at 12/18/2023. The price target of $25 was fulfilled within 1 day with a profit of $4.8 (23.76%) receiving and performance score of 237.62.

Average potential price target upside

of $47.25 (68.98%) on INO (INOVIO PHARMACEUTICALS).
of $41.54 (7.64%) on REGN (REGENERON PHARMACEUTICALS).
of $39.45 (76.44%) on REVB (REVELATION BIOSCIENCES).

ALXN Alexion Pharmaceuticals APDN Applied DNA Sciences APVO Aptevo Therapeutics INCY yte INO Inovio Pharmaceuticals MBRX Moleculin Biotech SEEL Seelos Therapeutics TFFP Tff Pharmaceuticals VVUS VIVUS CLDX Celldex Therapeutics PGNX Progenics Pharmaceuticals REGN Regeneron Pharmaceuticals AZRX AzurRx BioPharma CMRX Chimerix BPTH Bio Path Holdings FWBI First Wave BioPharma NOVN Novan REVB Revelation Biosciences KMPH KemPharm AKBA Akebia Ther BFRI Biofrontera CLRB Cellectar Biosciences HRTX Heron Therapeuti ACER Acer Therapeutics TTPH Tetraphase Pharmaceuticals CYCC Cyclacel Pharmaceuticals PBLA Panbela Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hartaj Singh (OPPENHEIMER)